Treace Medical (TMCI) Form 4: SVP's holdings at 205,092 shares including RSUs

Rhea-AI Filing Summary

Aaron Berutti, SVP, Sales at Treace Medical Concepts (TMCI), reported a change in beneficial ownership that results in 205,092 shares held beneficially. The filing shows a transaction dated 08/09/2025 listing 4,907 common shares with a recorded price of $0.

The reported total ownership explicitly includes 181,955 restricted stock units, per the form explanation. The disclosure is a Form 4 insider report reflecting an officer-level change in equity holdings; the filing does not provide additional context about the nature of the $0 price or whether the change arose from vesting, issuance, conversion, or another mechanism.

Positive

• Post-transaction beneficial ownership of 205,092 shares is explicitly reported, giving clear disclosure of officer holdings
• 181,955 restricted stock units are specifically identified, clarifying the composition of the reported stake

Negative

• None.

Insights

Securities Analyst

TL;DR: Officer-level equity change: 4,907-share item reported; total beneficial ownership now 205,092 shares including 181,955 RSUs.

The Form 4 shows a discrete transaction on 08/09/2025 and a post-transaction beneficial ownership of 205,092 shares. The entry records 4,907 common shares and a price of $0, and the explanatory note states inclusion of 181,955 restricted stock units. For investors, the most relevant facts are the scale of total holdings and the large RSU component, both explicitly stated. Because the form does not describe the mechanics of the $0 price, no definitive conclusion about cashless exercise, vesting, or issuance can be drawn from this filing alone.

Corporate Governance Expert

TL;DR: Governance disclosure is complete for a Form 4: officer reported beneficial ownership and RSU count, but the filing lacks transaction mechanics.

The report identifies the reporting person as an officer (SVP, Sales) and documents a post-transaction beneficial stake of 205,092 shares, with 181,955 units labeled as restricted stock units. The table shows a recorded price of $0 for a 4,907-share line item. From a governance perspective, the filing meets disclosure requirements by stating ownership levels and the RSU component; however, it does not provide narrative detail on whether the change resulted from vesting, a grant, conversion, or other plan activity, which limits interpretation of the transaction's governance implications.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berutti Aaron

(Last) (First) (Middle)

C/O TREACE MEDICAL CONCEPTS, INC.

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA FL 32081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Sales

3. Date of Earliest Transaction (Month/Day/Year)
08/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/09/2025		F		4,907	D	$0	205,092(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 181,955 restricted stock units.

	/s/ Lisa Taylor as Attorney-in-fact for Aaron Berutti	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What change did the TMCI Form 4 report for Aaron Berutti?

The Form 4 reports a transaction dated 08/09/2025 showing 4,907 common shares on the line item and a post-transaction beneficial ownership of 205,092 shares.

How many restricted stock units does the TMCI filing say the insider holds?

The filing's explanation states the reporting person holds 181,955 restricted stock units included in the total beneficial ownership.

Does the Form 4 indicate a price for the reported transaction?

Yes. The table shows a recorded price of $0 for the line item associated with the transaction.

What is Aaron Berutti's position at Treace Medical Concepts per the filing?

The filing identifies the reporting person as an officer with the title SVP, Sales.

Does the Form 4 explain whether the transaction was a vesting, grant, or sale?

No. The filing does not specify the mechanics of the transaction; it only lists the transaction line, the price of $0, and the resulting beneficial ownership amount.